Proposed Combination with Baxalta on Track to Close in Mid-2016
Shire plc (LSE: SHP, NASDAQ: SHPG) acknowledges the US Treasury notice
published on April 4, 2016, and anticipates the Baxalta transaction will
proceed as originally announced on January 11, 2016.
The combination of Shire and Baxalta is based on a strong strategic rationale
to create the leading global biotechnology company focused on rare diseases.
The company currently expects to complete its proposed combination by mid-2016
as previously announced.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.